ArticlePharmaceutical research2017
Detection and Specific Elimination of EGFR
Article in Pharmaceutical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Metabolotheranostics of pancreatic cancer by targeting choline, glutamine, and glucose transporters with photoimmunotherapy.Npj imaging · 2026Article
- Emerging Near-Infrared Targeted Imaging Pharmaceutics for Ovarian Cancer.Pharmaceutics · 2026Review
- Article
- Near-infrared photoimmunotherapy for effective elimination of ovarian cancer cells by inducing immunogenic cell death.Molecular therapy. Oncology · 2025Article
- SNAP-Tag-Based Recombinant Photoimmunotherapeutic Agents for the Selective Detection and Killing of Light-Accessible Melanotransferrin-Expressing Melanoma and Triple-Negative Breast Cancer.Cancer medicine · 2025Article
- Synthesis of site-specific Fab-drug conjugates using ADP-ribosyl cyclases.Protein science : a publication of the Protein Society · 2024Article
- Near Infrared Photoimmunotherapy: A Review of Recent Progress and Their Target Molecules for Cancer Therapy.International journal of molecular sciences · 2023Review
- Article
- The Potential of Antibody Technology and Silver Nanoparticles for Enhancing Photodynamic Therapy for Melanoma.Biomedicines · 2022Review
- EGFR-Targeted Photodynamic Therapy.Pharmaceutics · 2022Review
- Near-infrared photoimmunotherapy: design and potential applications for cancer treatment and beyond.Theranostics · 2022Review
- Toward Homogenous Antibody Drug Conjugates Using Enzyme-Based Conjugation Approaches.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies.Oncotarget · 2020Review
- Engineered Fragments of the PSMA-Specific 5D3 Antibody and Their Functional Characterization.International journal of molecular sciences · 2020Article
- Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma.Biomedicines · 2020Review
- Article
- One-step site-specific antibody fragment auto-conjugation using SNAP-tag technology.Nature protocols · 2019Article
- Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?Antibodies (Basel, Switzerland) · 2018Review
- ADAM17 inhibition enhances platinum efficiency in ovarian cancer.Oncotarget · 2018Article
- Human Antibody Fusion Proteins/Antibody Drug Conjugates in Breast and Ovarian Cancer.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTargeted theranostics is an alternative strategy in cancer management that aims to improve cancer detection and treatment simultaneously. This approach combines potent therapeutic and diagnostic agents with the specificity of different cell receptor ligands in one product. The success of antibody drug conjugates (ADCs) in clinical practice has encouraged the development of antibody theranostics conjugates (ATCs). However, the generation of homogeneous and pharmaceutically-acceptable ATCs remains a major challenge. The aim of this study is to detect and eliminate ovarian cancer cells on-demand using an ATC directed to EGFR.
methodsAn ATC with a defined drug-to-antibody ratio was generated by the site-directed conjugation of IRDye®700 to a self-labeling protein (SNAP-tag) fused to an EGFR-specific antibody fragment (scFv-425).
resultsIn vitro and ex vivo imaging showed that the ATC based on scFv-425 is suitable for the highly specific detection of EGFR
conclusionOur experiments provide a framework to create a versatile technology platform for the development of ATCs for precise detection and treatment of ovarian cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.